Consensus for the diagnosis, prognosis and treatment of feline mammary tumors

• Autor(a) principal: Geovanni Dantas Cassali
• Data de Publicação: 2018
• Outros Autores: Renata Afonso Sobral, Giovana Wingeter di Santis, Cristina Ghever Fernandes, Enio Ferreira, Breno Souza Salgado, Carlos Humberto da Costa Vieira-filho, Danielle Nascimento Silva, Emanoel Ferreira Martins-filho, Stéfane Valgas Teixeira, Fernanda Camargo Nunes, Cecília Bonolo de Campos, Karen Yumi Ribeiro Nakagaki, Angélica Cavalheiro Bertagnolli, Alessandra Estrela Lima, Gleidice Eunice Lavalle, Karine Araujo Damasceno, Andrigo Barboza de Nardi, Bruno Cogliati, Fernanda Vieira Amorim da Costa
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.11606/issn.1678-4456.bjvras.2018.135084; http://hdl.handle.net/1843/39981
• topic: Neoplasia; Felinos; Patologia; Terapêutica

The aim of the present prospective-retrospective study was to evaluate the response of high-risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high-risk of associ ated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non‑responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c‑kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c-kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.